ANTIVIRALS: European Training Network on Antiviral Drug Development.
EU contribution: EUR 3 849 087,6
MSCA-ITN-2014-ETN - Marie Sklodowska-Curie Innovative Training Networks (ITN-ETN)
Objective: Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens.
Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development.
The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary.
ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry.
Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.
EU contribution: EUR 510 748,56
ACADEMISCH ZIEKENHUIS LEIDEN
EU contribution: EUR 510 748,56
2333 ZA LEIDEN
EU contribution: EUR 498 432,96
IM NEUENHEIMER FELD 672
EU contribution: EUR 546 575,76
NEWPORT ROAD 30-36
CF24 ODE CARDIFF
UNIVERSITE D'AIX MARSEILLE
EU contribution: EUR 525 751,2
Boulevard Charles Livon 58
KATHOLIEKE UNIVERSITEIT LEUVEN
EU contribution: EUR 250 560
Oude Markt 13
ARATANA THERAPEUTICS NV
EU contribution: EUR 0
Project completion date : 2019-02-28 12:00:00
Major organization : UNIVERSITEIT UTRECHT
Address : Heidelberglaan 8
3584 CS Utrecht
Url : www.uu.nl/
Financier : EUROPEAN UNION (EU),
Financier address : European Union (EU)
Rue de la Loi 200/Wetstraat 200,
Tel: 32-2-2999696, 2993085
[c] 2016 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 6, 2016|
|Previous Article:||DEFORM: Define the global and financial impact of research misconduct.|
|Next Article:||SUSPOL: European Joint Doctorate in Organocatalysis and Sustainable Polymers.|